Tobin Schilke - 15 Feb 2023 Form 4 Insider Report for Revance Therapeutics, Inc.

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
15 Feb 2023
Net transactions value
-$69,243
Form type
4
Filing time
16 Feb 2023, 19:28:40 UTC
Previous filing
02 Feb 2023
Next filing
02 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Tax liability $69,243 -2,085 -3.8% $33.21 52,591 15 Feb 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares withheld by and surrendered to the Issuer on February 15, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of a Restricted Stock award (the "RSA") for 5,500 shares. The RSA vested in three equal annual installments from February 15, 2020.